Using Tissue Cell Culture To Make A Protein Or Polypeptide Patents (Class 435/70.1)
-
Patent number: 7629309Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: November 3, 2004Date of Patent: December 8, 2009Assignee: Zystor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Patent number: 7622106Abstract: A necrosis assays is performed with a cell expressing RIPK1 and RIP3 by (a) culturing the cell with a smac mimetic, caspase-8 inhibitor and TNF-?; and (b) detecting a resultant necrosis of the cell.Type: GrantFiled: March 6, 2009Date of Patent: November 24, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Xiaodong Wang, Sudan He, Lai Wang
-
Patent number: 7622127Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.Type: GrantFiled: June 20, 2007Date of Patent: November 24, 2009Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 7608427Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: October 27, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7608428Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: October 27, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7601812Abstract: The invention relates to active agents from parasitic worms, in particular Schistosoma mansoni, which induce a T-helper type 2 response (Th2 immune response).Type: GrantFiled: March 1, 2002Date of Patent: October 13, 2009Assignee: Forschungszentrum Borstel Zentrum fur Medizin und BiowissenschaftenInventors: Gabriele Schramm, Helmut Haas, Franco Falcone, Achim Gronow, Karin Haisch
-
Patent number: 7601518Abstract: The present invention concerns improved methods and compositions for producing a Neublastin polypeptide as well as local delivery of Neublastin to specific regions of the nervous system including the central nervous system and the eye for example by gene therapy. The invention also concerns Neublastin expression constructs which do not encode a pro-region of a Neublastin polypeptide, which expression construct result in increased secretion of bioactive Neublastin. The invention includes the delivery of Neublastin from transduced or transfected cells encapsulated into a macrocapsule with a semipermeable membrane. The invention further concerns mammalian cells capable of producing Neublastin in increased amounts.Type: GrantFiled: June 10, 2004Date of Patent: October 13, 2009Assignee: NsGene A/SInventors: Lars U. Wahlberg, Mette Gronborg, Philip Kusk, Jens Tornoe
-
Patent number: 7601514Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.Type: GrantFiled: November 26, 2007Date of Patent: October 13, 2009Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Daniel Tumas, Colin K. Watanabe, William I. Wood
-
Patent number: 7598058Abstract: This invention provides nucleic acid molecules encoding mutant human interleukin 13 molecules showing varying specificity for the restricted (IL4 independent) IL13 receptor. The mutant hIL13 molecules include those made by substituting the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Some of the mutants retain the ability to bind and cause signaling through IL13 receptors, while other mutants do not.Type: GrantFiled: August 24, 2004Date of Patent: October 6, 2009Assignee: Penn State Research FoundationInventors: Waldemar Debinski, Jeffrey P. Thompson
-
Patent number: 7598351Abstract: The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.Type: GrantFiled: December 3, 2004Date of Patent: October 6, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
-
Patent number: 7598080Abstract: A method of diagnosing the source of local, acute inflammation has been developed based on the discovery that white cells have different patterns of gene expression, and therefore protein markers, depending on the origin of the inflammation. These differences can be readily accessed by analysis of the white cells obtained at a site to be analyzed, for example, in the synovial fluid of a knee. The analysis, by comparison with the analysis of white cells present in known conditions, can be used to differentiate between inflammation due to bacterial infection, arthritis or gout, for example. The examples demonstrate differential gene expression in cells present in synovial fluid biopsies from patients with confirmed bacterial infection as compared to patients with aseptic loosening or patients with inflammation due to gout.Type: GrantFiled: August 9, 2005Date of Patent: October 6, 2009Inventor: Carl Deirmengian
-
Patent number: 7598030Abstract: This disclosure relates to methods for selecting antibodies having desirable characteristics from a population of diverse antibodies. More specifically, this disclosure provides methods for identifying antibodies which bind to cancer cells, but which do not bind to human red or white blood cells or normal tissue cells. Antibodies of the disclosure can be used for therapeutic and/or diagnostic purposes.Type: GrantFiled: July 8, 2005Date of Patent: October 6, 2009Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Hong Xin, Toshiaki Maruyama, Naveen Dakappagari
-
Patent number: 7595174Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 29, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7588919Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 15, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7588918Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 15, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7585622Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: November 2, 1999Date of Patent: September 8, 2009Assignees: Geron Corporation, The Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 7582447Abstract: It is intended to identify and provide a novel carnitine transporter gene participating in carnitine transport in the testis and epididymis and carnitine transporter which is a protein encoded by the gene. A protein comprising the amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting carnitine or its analog; and a gene encoding this protein.Type: GrantFiled: July 3, 2007Date of Patent: September 1, 2009Assignee: Human Cell Systems, Inc.Inventors: Hitoshi Endou, Yoshikatsu Kanai, Atsushi Enomoto
-
Patent number: 7582450Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 1, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7575894Abstract: The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu(5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) is exchanged with hydrophilic amino acid with a hydroxy group, specially serine, tyrosine or threonine, resulting in enhanced hydrophilic property of the protein surface.Type: GrantFiled: November 17, 2005Date of Patent: August 18, 2009Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung e.V.Inventors: Christian Schneider-Fresenius, Bernd Otto, Gero Waschütza
-
Patent number: 7572602Abstract: The invention concerns a recombinant nucleic acid molecule encoding an antimicrobial fusion peptidoglycan endopeptidase. The recombinant nucleic acid molecule according to the invention is formed from a nucleic acid encoding a bacterial endopeptidase (lysostaphin) from Staphylococcus simulans and a nucleic acid encoding a second endopeptidase (endolysin) module from Group B streptococcal bacteriophage B30. The encoded fusion endopeptidase has antimicrobial activity and kills both Staphylococcus bacteria and Streptococcus bacteria.Type: GrantFiled: December 5, 2005Date of Patent: August 11, 2009Assignee: The United States of America as represented by the Secretary of AgricultureInventor: David M. Donovan
-
Patent number: 7572895Abstract: The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.Type: GrantFiled: June 7, 2005Date of Patent: August 11, 2009Assignee: Raven Biotechnologies, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts, Ronghao Li
-
Patent number: 7569351Abstract: A novel apoptosis-associated gene p53AIPI is isolated by screening for a gene the expression of which is induced by p53. Since the protein encoded by this gene has an activity of inducing apoptosis, this gene is useful in developing effective therapeutic agents for cancer mediated by apoptosis. A method of screening for a compound controlling the induction of apoptosis which is expected as being useful in developing an apoptosis controlling agent.Type: GrantFiled: August 2, 2001Date of Patent: August 4, 2009Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Hirofumi Arakawa
-
Patent number: 7563879Abstract: The present invetion relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also realtes to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene eypression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.Type: GrantFiled: February 20, 2002Date of Patent: July 21, 2009Assignee: Intrexon CorporationInventor: Subba Reddy Palli
-
Patent number: 7560424Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: October 16, 2002Date of Patent: July 14, 2009Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Patent number: 7560439Abstract: The present invention provides a method of increasing the gene expression of transfected genes which includes the administration of a carnitine.Type: GrantFiled: September 27, 2004Date of Patent: July 14, 2009Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Pisano Claudio
-
Patent number: 7560278Abstract: The present invention relates to methods for culturing circovirus and in particular, porcine circovirus. The present invention provides compositions and methods for culturing porcine circovirus in mammalian cells expressing mammalian adenovirus E1 function.Type: GrantFiled: January 17, 2007Date of Patent: July 14, 2009Assignee: University of SaskatchewanInventors: Qiang Liu, Suresh K. Tikoo, Philip Willson, Lorne A. Babiuk
-
Patent number: 7560613Abstract: This invention relates to isolated nucleic acid fragments encoding trehalose metabolism enzymes, more specifically, alpha, alpha-trehalase, alpha, alpha-trehalose-phosphate synthase or trehalose-6-phosphate phosphatase. The invention also relates to the construction of a recombinant DNA construct encoding all or a portion of the alpha, alpha-trehalase, alpha, alpha-trehalose-phosphate synthase or trehalose-6-phosphate phosphatase, in sense or antisense orientation, wherein expression of the recombinant DNA construct results in production of altered levels of the alpha, alpha-trehalase, alpha, alpha-trehalose-phosphate synthase or trehalose-6-phosphate phosphatase in a transformed host cell.Type: GrantFiled: March 21, 2007Date of Patent: July 14, 2009Assignee: E. I. du Pont de Nemours and CompanyInventors: Perry G. Caimi, Saverio Carl Falco, Zude Weng
-
Patent number: 7557070Abstract: Systems including apparatus, methods, compositions, and kits for multiplexed analysis of biological systems using nonpositional and/or positional arrays of coded carriers.Type: GrantFiled: April 10, 2002Date of Patent: July 7, 2009Assignee: Millipore CorporationInventors: Ilya Ravkin, Simon Goldbard, William C. Hyun, Michael A. Zarowitz, Oren E. Beske
-
Patent number: 7556942Abstract: Tumor suppressor genes (TSGs) play a major role in the pathogenesis of human cancers. Here, a new TSG designated hippo (hpo) is described, and the human homolog mst2 is identified as an additional TSG. hpo as a gene that regulates both cell proliferation and cell death in Drosophila, and encodes a Ste-20 family protein kinase that binds to and phosphorylates the tumor suppressor protein Salvador (Sav), which is known to interact with the Warts (Wts) protein kinase. Loss of hpo results in elevated transcription of the cell cycle regulator cyclin E and the cell-death inhibitor diap1, leading to increased proliferation and reduced apoptosis. Further, hpo, sav, and wts define a pathway that regulates diap1 at the transcriptional level. A human homolog of hpo completely rescues the overgrowth phenotype of Drosophila hpo? mutants.Type: GrantFiled: July 15, 2004Date of Patent: July 7, 2009Assignee: Board of Regents, The University of Texas SystemInventor: Duojia Pan
-
Patent number: 7550256Abstract: Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin protein in such cells as compared to the level of cell surface expression of vimentin protein in a normal cell or a non-MDR neoplastic cell.Type: GrantFiled: December 15, 2003Date of Patent: June 23, 2009Assignee: Aurelium Biopharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
-
Patent number: 7544512Abstract: The present invention discloses a method of producing polypeptides, including insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs, by ligating genes in a tandem way. Also disclosed are the recombinant polypeptides produced by such a method. Using the method of this invention, 1 to 32 copies of GLP-1 (7-36) and/or GLP-1 analog genes may be expressed in tandem and the desired polypeptide can be obtained after cleavage of a fusion protein and further processes of separation and purification thus making possible the production of recombinant polypeptides, including recombinant GLP-1 (7-36) and/or GLP-1 analogs on a large scale, at a significantly reduced production cost.Type: GrantFiled: January 20, 2004Date of Patent: June 9, 2009Assignee: Shanhai Hua Yi Bio-Tech LabInventors: Yukun Sun, Dengxi Wu, Aizhen Wu, Zhiyong Zhu, Gang Yu, Jiaxiang Zhou, Shaoling Zhao
-
Patent number: 7544788Abstract: There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in FIG. 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.Type: GrantFiled: March 8, 2005Date of Patent: June 9, 2009Assignee: Janssen Pharmaceutica N.V.Inventor: Stefan Leo Jozef Masure
-
Patent number: 7541163Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: August 14, 2007Date of Patent: June 2, 2009Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse
-
Patent number: 7541164Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. Throughout their duration, the culturing processes of the invention involving two or more downward shifts in temperature sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein. In another aspect, the methods comprise the delayed addition of polyanionic compound during the culturing period.Type: GrantFiled: December 18, 2003Date of Patent: June 2, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Bernhard M. Schilling, Linda Matlock, Stephen G. Zegarelli, William V. Burnett, Christoph E. Joosten, Jonathan D. Basch, Sivakesava Sakhamuri, Steven S. Lee
-
Publication number: 20090136912Abstract: A carrier for cell culture is provided which improves the cell proliferativity in serum-free culture and which is free from risk from infection factor contamination. The gist of the features of the present invention is to be formed of a crosslinked poly (meth) acrylic acid (salt) particle (A) and an artificial polypeptide (P) having at least one cell-adhesive minimal amino acid sequence (X) in one molecule and to have a water retention value of from 2 to 50 g/g. The (A) is preferably a particle produced by reversed phase suspension polymerization of an aqueous monomer solution containing (meth)acrylic acid and/or an alkali metal salt of (meth)acrylic acid. The (P) preferably has at least one auxiliary amino acid sequence (Y) in one molecule of the (P). The (X) is preferably an Arg Gly Asp sequence.Type: ApplicationFiled: March 13, 2007Publication date: May 28, 2009Applicant: SANYO CHEMICAL INDUSTRIES, LTD.Inventors: Masato Kurokawa, Kazuhiro Takahashi
-
Patent number: 7537916Abstract: The present invention provides immortalized eukaryotic cells and methods useful for the production of immunologically active bivalent antibody fragments, such as F(ab?)2 fragments. The methods and cells of the invention result in a desirable ratio of bivalent to monovalent antibody fragments.Type: GrantFiled: February 14, 2008Date of Patent: May 26, 2009Assignee: Crucell Holland B.V.Inventors: David Halford Ashton Jones, Abraham Bout
-
Patent number: 7537930Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.Type: GrantFiled: July 14, 2006Date of Patent: May 26, 2009Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Zhengxing Qu, Chien Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang, Diane Nordstrom
-
Patent number: 7538200Abstract: The invention provides a thermal tolerant (thermostable) cellulase, AviIII, that is a member of the glycoside hydrolase (GH) family. AviIII was isolated and characterized from Acidothermus cellulolyticus and, like many cellulases, the disclosed polypeptide and/or its derivatives may be useful for the conversion of biomass into biofuels and chemicals.Type: GrantFiled: October 18, 2002Date of Patent: May 26, 2009Assignee: Alliance for Sustainable Energy, LLCInventors: Shi-You Ding, William S. Adney, Todd B. Vinzant, Michael E. Himmel
-
Patent number: 7534608Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: GrantFiled: July 2, 2008Date of Patent: May 19, 2009Assignee: Cythera, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Patent number: 7534861Abstract: A hybrid polypeptide composed of a p53 epitope peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that includes segments of DNA coding for the epitope peptide and the desired functional protein. An optional linking portion is contemplated. The linking portion of the epitope peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells transformed by the cloning vector is removed therefrom and purified by affinity chromatography techniques by use of an immobilized antibody specific to the antigenic portion of the epitope peptide. The protein is then cleaved from the isolated hybrid polypeptide with an appropriate proteolic enzyme or chemical agent, thereby releasing the mature functional protein in highly purified, highly active state.Type: GrantFiled: January 10, 2003Date of Patent: May 19, 2009Assignee: Ambergen, Inc.Inventors: Kenneth J. Rothschild, Sadanand Gite, Jerzy Olejnik, Mark Lim
-
Publication number: 20090123910Abstract: Methods for producing a protein extract from cells, such as cells or cellular samples containing viral proteins, are provided. In general terms, the methods may involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent such as a polyoxyethylene alkyl ether, neutralizing the pH of the intermediate composition to produce the protein extract. Such methods can be used in conjunction with methods for detecting one or more target proteins in a sample, such as viral proteins. Systems, kits and compositions for practicing the subject methods are also provided.Type: ApplicationFiled: November 14, 2007Publication date: May 14, 2009Inventors: Adrien P. Malick, Virginia M. Crews, Julie L. Rosales, Carrie S. Ferguson, Jeff H. Bruton, Robert J. Beadenkopf
-
Patent number: 7531324Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: September 13, 2006Date of Patent: May 12, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Roberto Falkenstein
-
Patent number: 7531327Abstract: Disclosed herein are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. By transfecting cells in culture with an apoptosis-inhibiting gene or vector, cells in culture can survive longer, resulting in extension of the state and yield of protein biosynthesis. Expression of the apoptosis-inhibitor within the cells, because it does not kill the cells, allows the cells, or an increased fraction thereof, to be maintained in culture for longer periods. This invention then allows for controlled, enhanced protein production of cell lines for commercial and research uses, particularly the enhanced production of growth factors, interferons, interleukins, hormones, enzymes, and monoclonal antibodies, and the like.Type: GrantFiled: July 25, 2005Date of Patent: May 12, 2009Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Zhengxing Qu, Eva Horak, Ivan D. Horak, Chien Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang
-
Patent number: 7527946Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: GrantFiled: June 15, 2004Date of Patent: May 5, 2009Assignee: Biogen Idec MA Inc.,Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Patent number: 7527801Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: GrantFiled: November 22, 2006Date of Patent: May 5, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Publication number: 20090111147Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.Type: ApplicationFiled: October 26, 2007Publication date: April 30, 2009Applicant: AMBRX, INCInventors: Zhenwei Miao, Junjie Liu, Thea Norman, Russell Driver
-
Patent number: 7524931Abstract: The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.Type: GrantFiled: June 23, 2003Date of Patent: April 28, 2009Assignee: Maxygen Holdings Ltd.Inventors: Bart Van Den Hazel, Anne Dam Jensen, Frank Bechnygaard, Kim Vilbour Andersen
-
Patent number: 7524661Abstract: Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm/280 nm and 1.359 at 260 nm/230 nm.Type: GrantFiled: February 1, 2006Date of Patent: April 28, 2009Assignee: Advanced Viral Research CorporationInventor: Bernard Friedland
-
Patent number: 7524649Abstract: The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of said modified growth hormone binding domains.Type: GrantFiled: December 6, 2002Date of Patent: April 28, 2009Assignee: Asterion LimitedInventors: Richard Ross, Jon Sayers, Peter Artymiuk
-
Patent number: 7521058Abstract: The invention relates to vaccines used in the eradication or control of pestivirus infections, particularly those used in pigs or ruminants. The invention provides nucleic acid, pestivirus-like particles and a pestivirus vaccine, comprising the nucleic acid or particles, which is capable of eliciting a proper immune response without having the ability to spread throughout the vaccinated animal, thereby avoiding the negative consequences of viral spread. Preferably, the immune response allows for serological discrimination between vaccinated animals and wild-type pestivirus infected animals.Type: GrantFiled: March 21, 2005Date of Patent: April 21, 2009Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Myra Noorely Widjojoatmodjo, Robertus Jacobus Maria Moormann, Petrus Antonius van Rijn